IP Library Patent Application 18534906
Patent Application
App. No. 18/534,906

COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/534,906
Abstract

The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):

Claims (395)

1 . A compound of Formula (I)

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein:

X is N(R a ), O, S or C(R b )(R c );

R a is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl; or

R a cyclizes with R 1 to form a 3- to 8-membered heterocycloalkyl;

R b is hydrogen or C 1 -C 6 alkyl;

R c is hydrogen or C 1 -C 6 alkyl;

or R b and R c , together with the atoms to which they are attached, form a C 3 -C 8 cycloalkyl;

Y is C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl, wherein the C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl is optionally substituted with one or more C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, 5- to 9-membered heteroaryl, halo, cyano, —R 4 OR 5 , —R 4 N(R 5 )(R 6 ), —R 4 SR 6 , —R 4 C(O)OR 6 , —R 4 C(O)N(R 7 )(R 8 ), —R 4 N(R 7 )C(O)R 8 , —R 4 S(O) t R 5 , —R 4 S(O) t N(R 7 )(R 8 ), —R 4 N(R 7 )S(O) t (R 8 ), —R 4 P(O)(R 5 ) 2 , or —R 4 SF 5 ;

R 1 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, —(CH 2 ) n —(C 3 -C 10 cycloalkyl), —(CH 2 ) n —(C 6 -C 10 aryl), —(CH 2 ) n -(3- to 8-membered heterocycloalkyl), or —(CH 2 ) n -(5- to 9-membered heteroaryl), —R 4 SR 6 , —R 4 C(O)OR 6 , —R 4 C(O)N(R 7 )(R 8 ), —R 4 N(R 7 )C(O)R 8 , —R 4 S(O) t R 5 , —R 4 S(O) t N(R 7 )(R 8 ), —R 4 N(R 7 )S(O) t (R 8 ), or —R 4 P(O)(R 5 ) 2 wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl is optionally substituted with one more halo, CN, C 1 -C 6 alkyl, —NR 4 R 5 , —R 4 OR 5 , an optionally substituted 3- to 8-membered heterocycloalkyl, an optionally substituted C 5 -C 10 aryl, or an optionally substituted 5- to 9-membered heteroaryl;

R 2 is hydrogen, halo, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, 5- to 9-membered heteroaryl, —R 4 OR 5 , —R 4 SR 6 , —R 4 C(O)OR 6 , —R 4 C(O)N(R 7 )(R 8 ), —R 4 N(R 7 )C(O)R 8 , —R 4 S(O) t R 5 , —R 4 S(O) t N(R 7 )(R 8 ), —R 4 N(R 7 )S(O) t (R 8 ), —R 4 P(O)(R 5 ) 2 , or —R 4 SF 5 , wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl is optionally substituted with one or more C 1 -C 6 alkyl, halo, or C 1 -C 6 haloalkyl;

R 3 is hydrogen, halo, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, 5- to 9-membered heteroaryl, —R 4 OR 5 , —R 4 SR 6 , —R 4 C(O)OR 6 , —R 4 C(O)N(R 7 )(R 8 ), —R 4 N(R 7 )C(O)R 8 , —R 4 S(O) t R 5 , —R 4 S(O) t N(R 7 )(R 8 ), —R 4 N(R 7 )S(O) t (R 8 ), —R 4 P(O)(R 5 ) 2 , or —R 4 SF 5 , wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl is optionally substituted with one or more C 1 -C 6 alkyl, halo, or C 1 -C 6 haloalkyl; or

R 2 and R 3 , together with the atoms to which they are attached, form a C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl, wherein the C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl is optionally substituted with one or more R 2a ;

R 2a is hydrogen, C 1 -C 6 alkyl, halo or C 1 -C 6 haloalkyl;

R 4 is a bond, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, wherein R 4 can only be a bond with —R 4 OR 5 ;

R 5 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl, wherein the alkyl is optionally substituted with one or more D;

R 6 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl;

R 7 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl;

R 8 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl; or

R 7 and R 8 , together with the atoms to which they are attached, form a 3- to 8-membered heterocycloalkyl;

n is an integer from 0 to 4; and

t is 1 or 2;

provided that R 1 is not C 2 or C 4 alkyl substituted with morpholinyl.

2 . The compound of claim 1 , wherein the compound is of formula (II):

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein:

Y is C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl, wherein the C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl is optionally substituted with one or more C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, 5- to 9-membered heteroaryl, halo, cyano, —R 4 OR 5 , —R 4 N(R 5 )(R 6 ), —R 4 SR 6 , —R 4 C(O)OR 6 , —R 4 C(O)N(R 7 )(R 8 ), —R 4 N(R 7 )C(O)R 8 , —R 4 S(O) t R 5 , —R 4 S(O) t N(R 7 )(R 8 ), —R 4 N(R 7 )S(O) t (R 8 ), —R 4 P(O)(R 5 ) 2 , or —R 4 SF 5 ;

R 1 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, —(CH 2 ) n —(C 3 -C 10 cycloalkyl), —(CH 2 ) n —(C 6 -C 10 aryl), —(CH 2 ) n -(3- to 8-membered heterocycloalkyl), or —(CH 2 ) n -(5- to 9-membered heteroaryl), —R 4 SR 6 , —R 4 C(O)OR 6 , —R 4 C(O)N(R 7 )(R 8 ), —R 4 N(R 7 )C(O)R 8 , —R 4 S(O) t R 5 , —R 4 S(O) t N(R 7 )(R 8 ), —R 4 N(R 7 )S(O) t (R 8 ), or —R 4 P(O)(R 5 ) 2 wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl is optionally substituted with one more halo, CN, C 1 -C 6 alkyl, —NR 4 R 5 , —R 4 OR 5 , an optionally substituted 3- to 8-membered heterocycloalkyl, an optionally substituted C 5 -C 10 aryl, or an optionally substituted 5- to 9-membered heteroaryl;

R 2 is hydrogen, halo, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, 5- to 9-membered heteroaryl, —R 4 OR 5 , —R 4 SR 6 , —R 4 C(O)OR 6 , —R 4 C(O)N(R 7 )(R 8 ), —R 4 N(R 7 )C(O)R 8 , —R 4 S(O) t R 5 , —R 4 S(O) t N(R 7 )(R 8 ), —R 4 N(R 7 )S(O) t (R 8 ), —R 4 P(O)(R 5 ) 2 , or —R 4 SF 5 , wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl is optionally substituted with one or more C 1 -C 6 alkyl, halo, or C 1 -C 6 haloalkyl;

R 3 is hydrogen, halo, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, 5- to 9-membered heteroaryl, —R 4 OR 5 , —R 4 SR 6 , —R 4 C(O)OR 6 , —R 4 C(O)N(R 7 )(R 8 ), —R 4 N(R 7 )C(O)R 8 , —R 4 S(O) t R 5 , —R 4 S(O) t N(R 7 )(R 8 ), —R 4 N(R 7 )S(O) t (R 8 ), —R 4 P(O)(R 5 ) 2 , or —R 4 SF 5 , wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl is optionally substituted with one or more C 1 -C 6 alkyl, halo, or C 1 -C 6 haloalkyl; or

R 2 and R 3 , together with the atoms to which they are attached, form a C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl, wherein the C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl is optionally substituted with one or more R 2a ;

R 2a is hydrogen, C 1 -C 6 alkyl, halo or C 1 -C 6 haloalkyl;

R 4 is a bond, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, wherein R 4 can only be a bond with —R 4 OR 5 ;

R 5 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl wherein the alkyl is optionally substituted with one or more D;

R 6 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl;

R 7 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl;

R 8 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl; or

R 7 and R 8 , together with the atoms to which they are attached, form a 3- to 8-membered heterocycloalkyl;

n is an integer from 0 to 4; and

t is 1 or 2;

provided that R 1 is not C 2 or C 4 alkyl substituted with morpholinyl.

3 . The compound of claim 1 , wherein Y is C 6 -C 10 aryl.

4 . The compound of claim 3 , wherein Y is phenyl.

5 . The compound of claim 4 , wherein the phenyl is substituted with one or more C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, halo, cyano, or —R 4 OR 5 .

6 . The compound of claim 1 , wherein Y is

7 . The compound of claim 1 , wherein R 2 is hydrogen or C 1 -C 6 alkyl.

8 . The compound of claim 1 , wherein R 2 and R 3 , together with the atoms to which they are attached, form a C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, or 5- to 9-membered heteroaryl, wherein the C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, or 5- to 9-membered heteroaryl is optionally substituted with one or more R 2a .

9 . The compound of claim 1 , wherein R 2a is hydrogen.

10 . The compound of claim 1 , wherein R 1 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, —(CH 2 ) n —(C 3 -C 10 cycloalkyl), —(CH 2 ) n —(C 6 -C 10 aryl), —(CH 2 ) n -(3- to 8-membered heterocycloalkyl), or —(CH 2 ) n -(5- to 9-membered heteroaryl).

11 . The compound of claim 10 , wherein the alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more halo, CN, C 1 -C 6 alkyl, C 6 -C 10 aryl, —NR 4 R 5 , or —R 4 OR 5 .

12 . The compound of claim 1 , wherein R 4 is a bond, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.

13 . The compound of claim 1 , wherein R 5 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 9-membered heteroaryl.

14 . The compound of claim 1 , wherein the compound of formula (II) is a compound of formula (II-a):

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein:

R 1 is C 1 -C 6 alkyl substituted with one more halo, —R 4 OR 5 , an optionally substituted 3- to 8-membered heterocycloalkyl, or an optionally substituted 5- to 9-membered heteroaryl; and

R 2 and R 3 , together with the atoms to which they are attached, form a C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl, wherein the C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 5 -C 10 aryl, or 5- to 9-membered heteroaryl is optionally substituted with one or more R 2a .

15 . The compound of claim 4 , wherein the compound of formula (II) is a compound of formula (II-h):

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof, wherein:

each R 2a is hydrogen;

R 1 is C 1 -C 6 alkyl, —(CH 2 ) n —(C 3 -C 10 cycloalkyl), —(CH 2 ) n —(C 6 -C 10 aryl), —(CH 2 ) n -(3- to 8-membered heterocycloalkyl), or —(CH 2 ) n -(5- to 9-membered heteroaryl), wherein the alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more halo, CN, C 1 -C 6 alkyl, C 6 -C 10 aryl, —NR 4 R 5 , or —R 4 OR 5 ; and

Y is C 6 -C 10 aryl, wherein the aryl is optionally substituted with one or more halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or —R 4 OR 5 ;

R 4 is a bond, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, wherein R 4 can only be a bond with —R 4 OR 5 ;

R 5 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 9-membered heteroaryl, wherein the alkyl is optionally substituted with one or more D; and

n is an integer from 0 to 4.

16 . The compound of claim 15 , wherein R 1 is C 1 -C 6 alkyl optionally substituted with one or more halo, CN, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 6 -C 10 aryl, —NR 4 R 5 , or —R 4 OR 5 .

17 . The compound of claim 15 , wherein R 1 is —(CH 2 ) n -(3- to 8-membered heterocycloalkyl) optionally substituted with one or more halo, C 1 -C 6 alkyl, or —R 4 OR 5 .

18 . The compound of claim 15 , wherein R 1 is —(CH 2 ) n —(C 3 -C 10 cycloalkyl) optionally substituted with one or more halo, C 1 -C 6 alkyl, or —R 4 OR 5 .

19 . The compound of claim 15 , wherein R 4 is a bond.

20 . The compound of claim 15 , wherein Y is C 6 -C 10 aryl optionally substituted with one or more halo, C 1 -C 6 alkyl, or —R 4 OR 5 .

21 . The compound of claim 1 selected from the group consisting of:

Cmp.

#

nomenclature

1

(S)-1-(4-chlorophenyl)-N-((tetrahydrofuran-2-yl)methyl)pyrido[3,4-

d]pyridazin-4-amine

2

(S)-4-(4-chlorophenyl)-N-((tetrahydrofuran-2-yl)methyl)pyrido[3,4-

d]pyridazin-1-amine

3

(R)-1-(4-chlorophenyl)-4-((tetrahydrofuran-2-yl)methoxy)pyrido[3,4-

d]pyridazine

4

(R)-4-(4-chlorophenyl)-1-((tetrahydrofuran-2-yl)methoxy)pyrido[3,4-

d]pyridazine

5

4-(4-chlorophenyl)-N-(tetrahydrofuran-2-ylmethyl)phthalazin-1-

amine

6

6-(4-bromophenyl)-N-[(2-methyltetrahydrofuran-2-

yl)methyl]pyridazin-3-amine

7

4-(4-bromophenyl)-N-(tetrahydrofuran-2-ylmethyl)phthalazin-1-

amine

8

4-(4-chlorophenyl)-N-[(2-methyltetrahydrofuran-2-

yl)methyl]phthalazin-1-amine

9

4-(4-chlorophenyl)-N-(tetrahydropyran-3-ylmethyl)phthalazin-1-

amine

10

4-(4-chlorophenyl)-N-(tetrahydropyran-4-ylmethyl)phthalazin-1-

amine

11

N-(tetrahydrofuran-2-ylmethyl)-4-[4-

(trifluoromethyl)phenyl]phthalazin-1-amine

12

4-(4-chlorophenyl)-N-[rac-(2R)-tetrahydrofuran-2-

yl]methyl]phthalazin-1-amine

13

4-(4-chlorophenyl)-N-[[rac-(2S)-tetrahydrofuran-2-

yl]methyl]phthalazin-1-amine

14

1-(4-chlorophenyl)-N-(tetrahydrofuran-2-ylmethyl)pyrido[3,4-

d]pyridazin-4-amine

15

4-(4-chlorophenyl)-N-(tetrahydrofuran-2-ylmethyl)pyrido[3,4-

d]pyridazin-1-amine

16

2-[[4-(4-chlorophenyl)phthalazin-1-yl]amino]ethanol

17

4-(4-chlorophenyl)-N-(tetrahydropyran-2-ylmethyl)phthalazin-1-

amine

18

4-(4-chlorophenyl)-N-(2-methoxyethyl)phthalazin-1-amine

19

4-(4-chlorophenyl)-N-methyl-N-(tetrahydrofuran-2-

ylmethyl)phthalazin-1-amine

20

4-(4-chloro-2-methyl-phenyl)-N-(tetrahydrofuran-2-

ylmethyl)phthalazin-1-amine

21

7-chloro-4-(4-chlorophenyl)-N-[rac-(2R)-tetrahydrofuran-2-

yl]methyl]phthalazin-1-amine

22

4-(4-chlorophenyl)-N-[(4-methyltetrahydrofuran-2-

yl)methyl]phthalazin-1-amine

23

(R)-N-((1,4-dioxan-2-yl)methyl)-4-(4-chlorophenyl)phthalazin-1-

amine

24

(S)-N-((1,4-dioxan-2-yl)methyl)-4-(4-chlorophenyl)phthalazin-1-

amine

25

4-(4-chlorophenyl)-N-[(5-methyltetrahydrofuran-2-

yl)methyl]phthalazin-1-amine

26

7-chloro-4-(4-chlorophenyl)-N-[rac-(2S)-tetrahydrofuran-2-

yl]methyl]phthalazin-1-amine

27

5-(4-chlorophenyl)-N-(tetrahydrofuran-2-ylmethyl)pyrido[2,3-

d]pyridazin-8-amine

28

8-(4-chlorophenyl)-N-(tetrahydrofuran-2-ylmethyl)pyrido[2,3-

d]pyridazin-5-amine

29

N-(tetrahydrofuran-2-ylmethyl)-4-[6-(trifluoromethyl)-3-

pyridyl]phthalazin-1-amine

30

4-(4-chlorophenyl)-N-(tetrahydrofuran-3-ylmethyl)phthalazin-1-

amine

31

N-(tetrahydrofuran-2-ylmethyl)-1-[4-

(trifluoromethyl)phenyl]pyrido[3,4-d]pyridazin-4-amine

32

N-(tetrahydrofuran-2-ylmethyl)-4-[4-

(trifluoromethyl)phenyl]pyrido[3,4-d]pyridazin-1-amine

33

N-(tetrahydrofuran-2-ylmethyl)-4-[5-(trifluoromethyl)-2-

pyridyl]phthalazin-1-amine

34

1-(4-chlorophenyl)-N-[rac-(2R)-tetrahydrofuran-2-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

35

1-[4-(1, 1-difluoroethyl)phenyl]-N-[rac-(2R)-tetrahydrofuran-2-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

36

N-[[rac-(2R)-tetrahydrofuran-2-yl]methyl]-1-[4-

(trifluoromethoxy)phenyl]pyrido[3,4-d]pyridazin-4-amine

37

rac-(2R)-1-[[1-(4-chlorophenyl)pyrido[3,4-d]pyridazin-4-

yl]amino]propan-2-ol

38

rac-(2S)-1-[[1-(4-chlorophenyl)pyrido[3,4-d]pyridazin-4-

yl]amino]propan-2-ol

39

1-(4-chlorophenyl)-N-(tetrahydropyran-4-ylmethyl)pyrido[3,4-

d]pyridazin-4-amine

40

rac-(2R)-1-[4-(4-chlorophenyl)pyrido[3,4-d]pyridazin-1-

yl]amino]propan-2-ol

41

rac-(2S)-1-[[4-(4-chlorophenyl)pyrido[3,4-d]pyridazin-1-

yl]amino]propan-2-ol

42

4-(4-chlorophenyl)-N-[[rac-(2R)-tetrahydrofuran-2-

yl]methyl]pyrido[3,4-d]pyridazin-1-amine

43

1-[4-(difluoromethoxy)phenyl]-N-[rac-(2R)-tetrahydrofuran-2-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

44

1-(4-cyclopropylphenyl)-N-[rac-(2R)-tetrahydrofuran-2-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

45

1-[4-(difluoromethyl)phenyl]-N-[[rac-(2R)-tetrahydrofuran-2-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

46

1-[[1-(4-chlorophenyl)pyrido[3,4-d]pyridazin-4-yl]amino]-2-methyl-

propan-2-ol

47

1-(4-chloro-3-fluoro-phenyl)-N-[[rac-(2R)-tetrahydrofuran-2-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

48

1-(4-chloro-2-methoxy-phenyl)-N-[[rac-(2R)-tetrahydrofuran-2-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

49

4-(4-chlorophenyl)-N-(2-furylmethyl)pyrido[3,4-d]pyridazin-1-amine

50

1-(4-chlorophenyl)-N-[rac-(3R)-tetrahydropyran-3-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

51

1-(4-chloro-2-fluoro-phenyl)-N-[rac-(2R)-tetrahydrofuran-2-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

52

1-[4-chloro-2-(trifluoromethyl)phenyl]-N-[[rac-(2R)-tetrahydrofuran-

2-yl]methyl]pyrido[3,4-d]pyridazin-4-amine

53

1-(4-chlorophenyl)-N-(2-oxabicyclo[2.1.1]hexan-1-

ylmethyl)pyrido[3,4-d]pyridazin-4-amine

54

1-(4-chlorophenyl)-N-[[rac-(3R)-tetrahydrofuran-3-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

55

4-(4-chlorophenyl)-N-[[rac-(2R)-tetrahydrofuran-2-

yl]methyl]thieno[2,3-d]pyridazin-7-amine

56

7-(4-chlorophenyl)-N-[[rac-(2R)-tetrahydrofuran-2-

yl]methyl]thieno[2,3-d]pyridazin-4-amine

57

6-(4-chlorophenyl)-4,5-dimethyl-N-[[rac-(2R)-tetrahydrofuran-2-

yl]methyl]pyridazin-3-amine

58

4-(4-chlorophenyl)-N-(2-oxabicyclo[2.1.1]hexan-1-

ylmethyl)pyrido[3,4-d]pyridazin-1-amine

59

N-[[rac-(2R)-tetrahydrofuran-2-yl]methyl]-1-[1-(2,2,2-trifluoroethyl)-

4-piperidyl]pyrido[3,4-d]pyridazin-4-amine

60

1-[4-chloro-2-(trifluoromethoxy)phenyl]-N-[rac-(2R)-

tetrahydrofuran-2-yl]methyl]pyrido[3,4-d]pyridazin-4-amine

61

4-(4-chlorophenyl)-N-[[rac-(2R)-tetrahydrofuran-2-

yl]methyl]furo[2,3-d]pyridazin-7-amine

62

1-(4-chlorophenyl)-N-[[rac-(3S)-tetrahydrofuran-3-

yl]methyl]pyrido[3,4-d]pyridazin-4-amine

63

1-(4-chlorophenyl)-N-[rac-(3S)-tetrahydrofuran-3-yl]pyrido[3,4-

d]pyridazin-4-amine

64

1-(4-chlorophenyl)-N-[rac-(3R)-tetrahydrofuran-3-yl]pyrido[3,4-

d]pyridazin-4-amine

65

3-[[1-(4-chlorophenyl)pyrido[3,4-d]pyridazin-4-yl]amino]propan-1-ol

66

1-(4-chlorophenyl)-N-(tetrahydrofuran-2-ylmethyl)-6,7-dihydro-5H-

cyclopenta[d]pyridazin-4-amine

67

4-(4-chlorophenyl)-N-[[rac-(3R)-tetrahydrofuran-3-

yl]methyl]pyrido[3,4-d]pyridazin-1-amine

68

4-(4-chlorophenyl)-N-[rac-(3S)-tetrahydrofuran-3-yl]pyrido[3,4-

d]pyridazin-1-amine

69

4-(4-chlorophenyl)-N-[rac-(3R)-tetrahydrofuran-3-yl]pyrido[3,4-

d]pyridazin-1-amine

70

3-[[4-(4-chlorophenyl)pyrido[3,4-d]pyridazin-1-yl]amino]propan-1-ol

71

4-[4-[[rac-(2R)-tetrahydrofuran-2-yl]methylamino]pyrido[3,4-

d]pyridazin-1-yl]benzonitrile

72

7-(4-chlorophenyl)-N-[[rac-(2R)-tetrahydrofuran-2-

yl]methyl]furo[2,3-d]pyridazin-4-amine

73

rac-(2R)-2-[[1-(4-chlorophenyl)pyrido[3,4-d]pyridazin-4-yl]amino]-

3,3,3-trifluoro-propan-1-ol

74

rac-(2S)-2-[[1-(4-chlorophenyl)pyrido[3,4-d]pyridazin-4-yl]amino]-

3,3,3-trifluoro-propan-1-ol

75

1-(4-chlorophenyl)-N-[[rac-(2R)-tetrahydrofuran-2-

yl]methyl]thieno[3,4-d]pyridazin-4-amine

76

6-(4-chlorophenyl)-N-[[rac-(2R)-tetrahydrofuran-2-yl]methyl]-5-

(trifluoromethyl)pyridazin-3-amine

77

4-(4-chlorophenyl)-N-[[rac-(3S)-tetrahydrofuran-3-

yl]methyl]pyrido[3,4-d]pyridazin-1-amine

78

1-(4-chlorophenyl)-N-[[rac-(2S)-1,4-dioxan-2-yl]methyl]pyrido[3,4-

d]pyridazin-4-amine

79

1-(4-chlorophenyl)-N-[[rac-(2R)-1,4-dioxan-2-yl]methyl]pyrido[3,4-

d]pyridazin-4-amine

80

1-(p-tolyl)-N-[[rac-(2R)-tetrahydrofuran-2-yl]methyl]pyrido[3,4-

d]pyridazin-4-amine,

81

4-(4-chlorophenyl)-N-[[rac-(2S)-1,4-dioxan-2-yl]methyl]pyrido[3,4-

d]pyridazin-1-amine

or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, or tautomer thereof.

22 . The compound of claim 15 , or a pharmaceutically acceptable salt or stereoisomer thereof selected from:

Cmp.

#

Structure

82

5-chloro-2-(4-((2-hydroxy-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-1-

yl)phenol

83

5-chloro-2-(4-((2-methoxy-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-1-

yl)phenol

84

5-methoxy-2-(4-((2-methoxy-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-1-

yl)phenol

85

2-(4-((2-methoxy-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-1-yl)-5-

methylphenol

86

5-bromo-2-(4-((2-methoxy-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-1-

yl)phenol

87

2-(4-((2-methoxy-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-1-yl)-5-

(trifluoromethyl)phenol

88

2-(4-((2-methoxy-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-1-yl)-5-

(trifluoromethoxy)phenol

89

(S)-5-chloro-2-(4-((tetrahydrofuran-3-yl)amino)pyrido[3,4-d]pyridazin-1-

yl)phenol

90

5-chloro-2-(4-((3-hydroxy-3-methylbutyl)amino)pyrido[3,4-d]pyridazin-1-

yl)phenol

91

(S)-5-chloro-2-(4-(((3,3-difluorocyclopentyl)methyl)amino)pyrido[3,4-

d]pyridazin-1-yl)phenol

92

(S)-5-chloro-2-(4-(((tetrahydrofuran-3-yl)methyl)amino)pyrido[3,4-

d]pyridazin-1-yl)phenol

93

(S)-5-chloro-2-(4-(((1-methylpyrrolidin-2-yl)methyl)amino)pyrido[3,4-

d]pyridazin-1-yl)phenol

94

(R)-5-chloro-2-(4-(((3-fluorotetrahydrofuran-3-yl)methyl)amino)pyrido[3,4-

d]pyridazin-1-yl)phenol

95

5-chloro-2-(4-(((1S,2S)-2-hydroxycyclopentyl)amino)pyrido[3,4-d]pyridazin-1-

yl)phenol

96

5-chloro-2-(4-(((1-(hydroxymethyl)cyclopropyl)methyl)amino)pyrido[3,4-

d]pyridazin-1-yl)phenol

97

(R)-5-chloro-2-(4-((3,3,3-trifluoro-2-methoxypropyl)amino)pyrido[3,4-

d]pyridazin-1-yl)phenol

98

(S)-5-chloro-2-(4-((1-methylpyrrolidin-3-yl)amino)pyrido[3,4-d]pyridazin-1-

yl)phenol

99

5-chloro-2-(4-((2-(methoxy-d3)-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-

1-yl)phenol

100

(R)-5-chloro-2-(4-((1-methoxypropan-2-yl)amino)pyrido[3,4-d]pyridazin-1-

yl)phenol

101

(R)-5-chloro-2-(4-(((4-methylmorpholin-2-yl)methyl)amino)pyrido[3,4-

d]pyridazin-1-yl)phenol

102

3-((1-(4-chloro-2-hydroxyphenyl)pyrido[3,4-d]pyridazin-4-yl)amino)-2,2-

dimethylpropanenitrile

103

(R)-5-chloro-2-(4-(((4-methylmorpholin-2-yl)methyl)amino)pyrido[3,4-

d]pyridazin-1-yl)phenol

104

5-chloro-2-(4-((4-fluorobenzyl)amino)pyrido[3,4-d]pyridazin-1-

yl)phenol

105

(R)-5-chloro-2-(4-((5,5-dimethyltetrahydrofuran-3-yl)amino)pyrido[3,4-

d]pyridazin-1-yl)phenol

23 . The compound of claim 1 , wherein R 5 is C 1 -C 6 alkyl substituted with D.

24 . The compound of claim 15 , wherein R 5 is C 1 -C 6 alkyl substituted with D.

25 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

26 . A pharmaceutical composition comprising the compound of claim 21 and a pharmaceutically acceptable carrier.

27 . A pharmaceutical composition comprising the compound of claim 15 and a pharmaceutically acceptable carrier.

28 . A pharmaceutical composition comprising the compound of claim 22 and a pharmaceutically acceptable carrier.

29 . A method of treating or preventing an NLRP3-related disease or disorder, comprising administering to the subject at least one therapeutically effective amount of the compound of claim 1 .

30 . The method of claim 1 , wherein the NLRP3-related disease or disorder is inflammation, an auto-immune disease, a cancer, an infection, a disease or disorder of the central nervous system, a metabolic disease, a cardiovascular disease, a respiratory disease, a kidney disease, a liver disease, an ocular disease, a skin disease, a lymphatic disease, a rheumatic disease, a psychological disease, graft versus host disease, allodynia, or an NLRP3-related disease in a subject that has been determined to carry a germline or somatic non-silent mutation in NLRP3.